Stock Events

Stock Events

Chemomab Therapeutics 

€0
19
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-26.43MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2QV.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Galapagos NV
GLPG
Mkt Cap2.09B
Galapagos NV specializes in drug discovery for fibrosis and inflammatory diseases, overlapping with Chemomab's research areas.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Madrigal Pharmaceuticals is involved in developing therapies for fibrosis and NASH, similar to Chemomab's focus areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong portfolio in liver diseases, including fibrosis and NASH, competing with Chemomab's pipeline.
Viking Therapeutics
VKTX
Mkt Cap4.3B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, directly competing with Chemomab.
Agenus
AGEN
Mkt Cap126.5M
Agenus Inc. is involved in immuno-oncology but also explores inflammatory diseases, potentially overlapping with Chemomab's therapeutic areas.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a broad portfolio that includes treatments for inflammatory diseases, indirectly competing with Chemomab in the broader market for anti-inflammatory treatments.

About

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Show more...
CEO
ISIN
US16385C2035
WKN
000A41FPN

Listings

F
DE
2QV.F
XNAS
US
CMMB
BOATS
BOATS
CMMB.BOATS

0 Comments

Share your thoughts

FAQ

What is Chemomab Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Chemomab Therapeutics stocks are traded under the ticker 2QV.F.
What is Chemomab Therapeutics revenue for the last year?▼
Chemomab Therapeutics revenue for the last year amounts to 0 EUR.
What is Chemomab Therapeutics net income for the last year?▼
2QV.F net income for the last year is -26.43M EUR.
When did Chemomab Therapeutics complete a stock split?▼
The last stock split for Chemomab Therapeutics was on August 26, 2025 with a ratio of 1:4.